The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC-Reference-Cited by-同舟云学术

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC

Published:2016-09 Issue:9 Volume:11 Page:1503-1510
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Liu Si-Yang,Gou Lan-Ying,Li An-Na,Lou Na-Na,Gao Hong-Fei,Su Jian,Yang Jin-Ji,Zhang Xu-Chao,Shao Yang,Dong Zhong-Yi,Zhou Qing,Zhong Wen-Zhao,Wu Yi-Long

Funder

Key Technologies Research and Development Program

Guangzhou Science and Technology Bureau

Key Laboratory Program of Guangdong

National Health and Family Planning Commission

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs;Kris;JAMA,2014

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

5. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol,2012

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unusual Synchronous Multiple Primary Early-Stage Lung Adenocarcinoma with Concomitant MET Exon 14 Skipping, PIK3CA and KRAS Mutations: A Case Report;Case Reports in Oncology;2024-08-07

2. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION;British Journal of Cancer;2024-04-04

3. Long‐term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study;Cancer Science;2024-02-25

4. Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions;Cells;2024-01-25

5. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer;Therapeutic Advances in Medical Oncology;2024-01